J Glaucoma:进行上眼睑分裂手术以促进青光眼引流装置的植入!

2017-09-22 cuiguizhong MedSci原创

爱荷华州立大学眼科与视觉科学系的Provencher LM近日在J Glaucoma发表了他们最近的研究工作,他们在文章中介绍了一项用于上眼睑垂直分裂的新的治疗方案。这项技术传统上用于维持眼窝畅通,以便于对不能进行手术的患者植入青光眼引流装置。

爱荷华州立大学眼科与视觉科学系的Provencher LM近日在J Glaucoma发表了他们最近的研究工作,他们在文章中介绍了一项用于上眼睑垂直分裂的新的治疗方案。这项技术传统上用于维持眼窝畅通,以便于对不能进行手术的患者植入青光眼引流装置。


他们采用案例研究的方法,描述了一个眼外肌完全受限制的莫比斯综合征的病例,其次是一例由于慢性过敏性皮炎引起的睑缘裂缝瘢痕性狭窄的病例。两名患者都患有严重的医学上不受控制的青光眼,但是由于手术效果不理想,导致青光眼引流装置植入不完全。这两例病例都发生了上眼睑的垂直分裂,这可以满足眼球上半球充分暴露并成功植入青光眼引流装置。

因此,他们认为,各种先天性或获得性因素导致睑裂裂缝变小,或者使眼外运动受到局限。当这些患者出现晚期青光眼症状时,不良的手术可能会阻碍必要的外科手术进行治疗。使用垂直上眼睑分割技术可以进入眼球上半球,并且便于植入青光眼引流装置。这项工作为眼科临床医生和青光眼患者提供了另一种治疗方案。

原文出处:

Provencher, L.M., et al., Upper Eyelid Splitting to Facilitate the Insertion of Glaucoma Drainage Devices. J Glaucoma, 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1914186, encodeId=144519141863e, content=<a href='/topic/show?id=5ee629957f' target=_blank style='color:#2F92EE;'>#AUC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2995, encryptionId=5ee629957f, topicName=AUC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun Mar 25 01:20:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684100, encodeId=796a1684100f0, content=<a href='/topic/show?id=bf59e2814cf' target=_blank style='color:#2F92EE;'>#眼睑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72814, encryptionId=bf59e2814cf, topicName=眼睑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8928034409, createdName=zhangbaojun, createdTime=Sun May 06 17:20:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520407, encodeId=0f7b152040e30, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Sun Sep 24 13:20:00 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2018-03-25 aliceclz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1914186, encodeId=144519141863e, content=<a href='/topic/show?id=5ee629957f' target=_blank style='color:#2F92EE;'>#AUC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2995, encryptionId=5ee629957f, topicName=AUC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun Mar 25 01:20:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684100, encodeId=796a1684100f0, content=<a href='/topic/show?id=bf59e2814cf' target=_blank style='color:#2F92EE;'>#眼睑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72814, encryptionId=bf59e2814cf, topicName=眼睑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8928034409, createdName=zhangbaojun, createdTime=Sun May 06 17:20:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520407, encodeId=0f7b152040e30, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Sun Sep 24 13:20:00 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1914186, encodeId=144519141863e, content=<a href='/topic/show?id=5ee629957f' target=_blank style='color:#2F92EE;'>#AUC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2995, encryptionId=5ee629957f, topicName=AUC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun Mar 25 01:20:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684100, encodeId=796a1684100f0, content=<a href='/topic/show?id=bf59e2814cf' target=_blank style='color:#2F92EE;'>#眼睑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72814, encryptionId=bf59e2814cf, topicName=眼睑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d8928034409, createdName=zhangbaojun, createdTime=Sun May 06 17:20:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520407, encodeId=0f7b152040e30, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Sun Sep 24 13:20:00 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2017-09-24 jiyangfei